235 related articles for article (PubMed ID: 11287684)
1. Gene therapy for HIV.
Lever AM
Sex Transm Infect; 2001 Apr; 77(2):93-6. PubMed ID: 11287684
[No Abstract] [Full Text] [Related]
2. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.
Smythe JA; Symonds G
Inflamm Res; 1995 Jan; 44(1):11-5. PubMed ID: 7664023
[No Abstract] [Full Text] [Related]
3. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
Rossi JJ; Sarver N
Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448
[No Abstract] [Full Text] [Related]
4. RNA as a target for developing antivirals.
McKnight KL; Heinz BA
Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic antisense and ribozymes.
Rossi JJ
Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
[TBL] [Abstract][Full Text] [Related]
6. HIV and Ribozymes.
Scarborough RJ; Gatignol A
Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
[TBL] [Abstract][Full Text] [Related]
7. Antisense treatment of viral infection.
Whitton JL
Adv Virus Res; 1994; 44():267-303. PubMed ID: 7817875
[TBL] [Abstract][Full Text] [Related]
8. T-bodies as antiviral agents.
Bitton N; Debre P; Eshhar Z; Gorochov G
Curr Top Microbiol Immunol; 2001; 260():271-300. PubMed ID: 11443878
[No Abstract] [Full Text] [Related]
9. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
Akhtar S; Rossi JJ
J Antimicrob Chemother; 1996 Aug; 38(2):159-65. PubMed ID: 8877530
[No Abstract] [Full Text] [Related]
10. RNA-based gene therapy for HIV infection.
Dorman N; Lever AM
HIV Med; 2001 Apr; 2(2):114-22. PubMed ID: 11737388
[No Abstract] [Full Text] [Related]
11. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
13. Antisense technology for cancer therapy: does it make sense?
Carter G; Lemoine NR
Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718
[No Abstract] [Full Text] [Related]
14. Intrabodies as antiviral agents.
Marasco WA
Curr Top Microbiol Immunol; 2001; 260():247-70. PubMed ID: 11443877
[No Abstract] [Full Text] [Related]
15. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
AIDS Patient Care STDS; 1996 Dec; 10(6):375-6. PubMed ID: 11361558
[No Abstract] [Full Text] [Related]
16. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
17. Making sense of antisense.
Murakami A
Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507
[No Abstract] [Full Text] [Related]
18. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
[TBL] [Abstract][Full Text] [Related]
19. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
Alvarez-Salas LM; BenÃtez-Hess ML; DiPaolo JA
Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
[TBL] [Abstract][Full Text] [Related]
20. Antisense strategies in degenerative joint diseases: sense or nonsense?
Huber LC; Distler O; Gay RE; Gay S
Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
